Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-kappaB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN).
Purity:
95.00%
CAS Number:
[1000676-41-4]
Target:
Virus Protease
* VAT and and shipping costs not included. Errors and price changes excepted